Literature DB >> 29382702

Genome-Wide Association Studies in Glioma.

Ben Kinnersley1, Richard S Houlston1, Melissa L Bondy2.   

Abstract

Since the first reports in 2009, genome-wide association studies (GWAS) have been successful in identifying germline variants associated with glioma susceptibility. In this review, we describe a chronological history of glioma GWAS, culminating in the most recent study comprising 12,496 cases and 18,190 controls. We additionally summarize associations at the 27 glioma-risk SNPs that have been reported so far. Future efforts are likely to be principally focused on assessing association of germline-risk SNPs with particular molecular subgroups of glioma, as well as investigating the functional basis of the risk loci in tumor formation. These ongoing studies will be important to maximize the impact of research into glioma susceptibility, both in terms of insight into tumor etiology as well as opportunities for clinical translation. Cancer Epidemiol Biomarkers Prev; 27(4); 418-28. ©2018 AACRSee all articles in this CEBP Focus section, "Genome-Wide Association Studies in Cancer." ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29382702      PMCID: PMC5931394          DOI: 10.1158/1055-9965.EPI-17-1080

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  133 in total

1.  A genome-wide association study yields five novel thyroid cancer risk loci.

Authors:  Julius Gudmundsson; Gudmar Thorleifsson; Jon K Sigurdsson; Lilja Stefansdottir; Jon G Jonasson; Sigurjon A Gudjonsson; Daniel F Gudbjartsson; Gisli Masson; Hrefna Johannsdottir; Gisli H Halldorsson; Simon N Stacey; Hannes Helgason; Patrick Sulem; Leigha Senter; Huiling He; Sandya Liyanarachchi; Matthew D Ringel; Esperanza Aguillo; Angeles Panadero; Enrique Prats; Almudena Garcia-Castaño; Ana De Juan; Fernando Rivera; Li Xu; Lambertus A Kiemeney; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; Hoskuldur Kristvinsson; Romana T Netea-Maier; Thorvaldur Jonsson; Jose I Mayordomo; Theo S Plantinga; Hannes Hjartarson; Jon Hrafnkelsson; Erich M Sturgis; Unnur Thorsteinsdottir; Thorunn Rafnar; Albert de la Chapelle; Kari Stefansson
Journal:  Nat Commun       Date:  2017-02-14       Impact factor: 14.919

Review 2.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk.

Authors:  Mahboobeh Safaeian; Preetha Rajaraman; Patricia Hartge; Meredith Yeager; Martha Linet; Mary Ann Butler; Avima M Ruder; Mark P Purdue; Ann Hsing; Laura Beane-Freeman; Jane A Hoppin; Demetrius Albanes; Stephanie J Weinstein; Peter D Inskip; Alina Brenner; Nathaniel Rothman; Nilanjan Chatterjee; Elizabeth M Gillanders; Stephen J Chanock; Sophia S Wang
Journal:  Cancer Causes Control       Date:  2013-08-01       Impact factor: 2.506

5.  Chromosome 7p11.2 (EGFR) variation influences glioma risk.

Authors:  Marc Sanson; Fay J Hosking; Sanjay Shete; Diana Zelenika; Sara E Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean-Yves Delattre; Khe Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao-Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B Robertson; Kenneth Muir; Sarah Hepworth; Anthony Swerdlow; Minouk J Schoemaker; H-Erich Wichmann; Martina Müller; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Asta Försti; Kari Hemminki; Mark Lathrop; Melissa Bondy; Richard S Houlston; Matthias Simon
Journal:  Hum Mol Genet       Date:  2011-04-29       Impact factor: 6.150

6.  ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma.

Authors:  Victoria Sanz-Moreno; Cedric Gaggioli; Maggie Yeo; Jean Albrengues; Fredrik Wallberg; Amaya Viros; Steven Hooper; Richard Mitter; Chloé C Féral; Martin Cook; James Larkin; Richard Marais; Guerrino Meneguzzi; Erik Sahai; Chris J Marshall
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

7.  Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma.

Authors:  A Iavarone; K K Matthay; T M Steinkirchner; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

8.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

9.  Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.

Authors:  Sahitya K Denduluri; Olumuyiwa Idowu; Zhongliang Wang; Zhan Liao; Zhengjian Yan; Maryam K Mohammed; Jixing Ye; Qiang Wei; Jing Wang; Lianggong Zhao; Hue H Luu
Journal:  Genes Dis       Date:  2015-03-01

10.  Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222.

Authors:  V Enciso-Mora; F J Hosking; A L Di Stefano; D Zelenika; S Shete; P Broderick; A Idbaih; J-Y Delattre; K Hoang-Xuan; Y Marie; M Labussière; A Alentorn; P Ciccarino; M Rossetto; G Armstrong; Y Liu; K Gousias; J Schramm; C Lau; S J Hepworth; M Schoemaker; K Strauch; M Müller-Nurasyid; S Schreiber; A Franke; S Moebus; L Eisele; A Swerdlow; M Simon; M Bondy; M Lathrop; M Sanson; R S Houlston
Journal:  Br J Cancer       Date:  2013-04-09       Impact factor: 7.640

View more
  10 in total

1.  The genetic polymorphisms of angiotensin converting enzyme insertion/deletion and glioma susceptibility: A meta-analysis.

Authors:  Meili Sun; Yuying Fang; Shuzhen Ma; Ximei Gao; Yuping Sun
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636

2.  Meta-Analyses of Splicing and Expression Quantitative Trait Loci Identified Susceptibility Genes of Glioma.

Authors:  C Pawan K Patro; Darryl Nousome; Rose K Lai
Journal:  Front Genet       Date:  2021-04-15       Impact factor: 4.772

3.  Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population.

Authors:  Jigao Feng; Yibin Ouyang; Dedong Xu; Qinglong He; Dayuan Liu; Xudong Fan; Pengxiang Xu; Yehe Mo
Journal:  BMC Cancer       Date:  2020-10-09       Impact factor: 4.430

4.  Genome-Wide Association Study Identifies Multiple Susceptibility Loci for Malignant Neoplasms of the Brain in Taiwan.

Authors:  Jang-Chun Lin; Yi-Chieh Wu; Fu-Chi Yang; Jo-Ting Tsai; David Yc Huang; Wei-Hsiu Liu
Journal:  J Pers Med       Date:  2022-07-18

5.  Expression and Prognostic Value of ARID5A and its Correlation With Tumor-Infiltrating Immune Cells in Glioma.

Authors:  Quan Zhou; Jinping Zhou; Jingyi Fan
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

Review 6.  Use of Mendelian Randomization for Identifying Risk Factors for Brain Tumors.

Authors:  Amy Elizabeth Howell; Jie Zheng; Philip C Haycock; Alexandra McAleenan; Caroline Relton; Richard M Martin; Kathreena M Kurian
Journal:  Front Genet       Date:  2018-11-12       Impact factor: 4.599

7.  Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.

Authors:  Guangting Qiu; Wenjie Tong; Chenghao Jiang; Qingsong Xie; Jingfang Zou; Cong Luo; Jianwei Zhao; Lu Zhang; Jiang Zhao
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 8.  Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance.

Authors:  Zulfikar Azam; Shing-Shun Tony To; Bakhos A Tannous
Journal:  Adv Sci (Weinh)       Date:  2020-09-28       Impact factor: 16.806

9.  A functional variant on 20q13.33 related to glioma risk alters enhancer activity and modulates expression of multiple genes.

Authors:  Mourad Wagdy Ali; C Pawan K Patro; Jacqueline Jufen Zhu; Christopher H Dampier; Sarah J Plummer; Cem Kuscu; Mazhar Adli; Ching Lau; Rose K Lai; Graham Casey
Journal:  Hum Mutat       Date:  2020-11-22       Impact factor: 4.700

10.  A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B-AS1.

Authors:  Mourad Wagdy Ali; C Pawan K Patro; Matthew Devall; Christopher H Dampier; Sarah J Plummer; Cem Kuscu; Mazhar Adli; Rose K Lai; Graham Casey
Journal:  Hum Mutat       Date:  2021-06-29       Impact factor: 4.878

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.